Clinical trials: Attention Deficit Disorder With Hyperactivity (ADHD)
ADHD, PMS
Prevalence of Lidocaine Ineffectiveness in Adults With and Without ADHD
This work will assess the prevalence in the general population of the ineffectiveness of the anesthetic Lidocaine compared to males with ADHD and females with ADHD with or without PMS.
- Trial name
- NCT03676725
- Testing
- Lidocaine gel
- Where
- 2 sites in United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- PhenoSolve, LLC
ADHD
A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD)
The primary objective of this study is to assess the time of onset of Vyvanse compared to placebo, in the analog classroom as measured by the Swanson, Kotkin, Agler, M.
- Trial name
- NCT00500149
- Testing
- Vyvanse (lisdexamfetamine dimesylate)
- Where
- 9 sites in United States
- Volunteers
- 129 people
- Sponsor
- Shire
Attention Deficit Disorder With Hyperactivity, Conduct Disorder
Brain Indices of Stimulant Treatment in Drug-Naive Youth at Risk for Substance Use Disorder
Childhood ADHD and comorbid oppositional defiant disorder (ODD) and conduct disorder (CD) are considered risk factors for subsequent substance abuse, and youth with both ADHD and ODD/CD are at greatest risk.
- Conditions
- Attention Deficit Disorder With Hyperactivity, Conduct Disorder, Substance Abuse
- Trial name
- NCT04170738
- Testing
- Adderall
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Jeffrey Newcorn
ADHD
The Effects of ADHD Medication (TEAM) Study
This study evaluates the effects of receiving and then discontinuing methylphenidate (MPH) in children with ADHD. After receiving MPH for 8 weeks, participants will be randomized to either discontinue MPH (and receive placebo) OR…
- Trial name
- TEAM (NCT02293655)
- Testing
- OROS-Methylphenidate (MPH)
- Where
- 2 sites in United States
- Volunteers
- 204 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
ADHD
Prevention of Cigarette Smoking in Attention Deficit Hyperactivity Disorder (ADHD) Youth With Concerta
This study will consist of a six-week open-label treatment period with an extended duration methylphenidate (OROS MPH) followed by subsequent monthly visits for 24 months in a large sample of youths aged 12-17 who meet Diagnostic…
- Trial name
- NCT00181714
- Testing
- methylphenidate HCl (Concerta)
- Where
- United States
- Volunteers
- 203 people
- Sponsor
- Massachusetts General Hospital
ADHD, ADD
ADHD Electrophysiological Subtypes and Implications in Transcranial Direct-current Stimulation
In the present study the aim is to examine whether transcranial direct-current stimulation (tDCS) generated excitability changes and induce modifications of functional cortical architecture in Attention Deficit Hyperactivity…
- Trial name
- tdcs&adhd (NCT01649232)
- Testing
- Active tDCS
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Spanish Foundation for Neurometrics Development
ADHD, Smoking
Smoking Cessation for Adults With Attention Deficit Hyperactivity Disorder (ADHD)
The objective of this study is to evaluate whether Osmotic-Release Methylphenidate (OROS MPH), relative to placebo, increases the effectiveness of standard smoking treatment (i.e., nicotine patch and individual smoking cessation…
- Trial name
- NCT00253747
- Testing
- Osmotic-Release Methylphenidate
- Where
- 6 sites in United States
- Volunteers
- 255 people
- Sponsor
- University of Cincinnati
ADHD
Effects of Noise Cancelling Headphones on Neurocognitive and Academic Outcomes in ADHD
The purpose of this study is to evaluate performance on the Attention Deficit Hyperactivity Disorder ( ADHD) Battery of the Cambridge Automated Neuropsychological Test Battery (CANTAB), including spatial working memory…
- Trial name
- NCT03216512
- Testing
- Use of Noise Cancelling Headphones
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Duke University
Attention Deficit Hyperactivity Disorder Symptoms
Implementation Strategy Resource Package for Behavioral Classroom Interventions: Pilot Test
The purpose of this study is to pilot test for feasibility and initial promise an implementation strategy resource package that aims to support teachers in using behavioral classroom management interventions for children with…
- Trial name
- NCT05489081
- Testing
- Positive Behavior Management Toolkit
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Children's Hospital of Philadelphia
Attention Deficit Hyperactivity Disorder, Autism Spectrum Disorder
GroundsKeeper: A Qualitative Study of Applied Game-based Interactives in Special Education Programs
The purpose of this study is to examine the use of, and reaction to, one particular software application(GroundsKeeper) delivered on unique platform - Sifteo cubes (www.sifteo.com).
- Conditions
- Attention Deficit Hyperactivity Disorder, Autism Spectrum Disorder, Pervasive Developmental Disorder, Asperger's Disorder
- Trial name
- NCT01808066
- Testing
- Groundskeeper
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- CogCubed, Corp
ADHD, Attention Deficit Hyperactivity Disorder
Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301
A Phase 3, randomized, double-blind, placebo-controlled, multi-center, fixed-dose, parallel-group efficacy and safety study in a pediatric population (6-17) with Attention-Deficit/Hyperactivity Disorder (ADHD) using CTx-1301…
- Conditions
- ADHD, Attention Deficit Hyperactivity Disorder, ADHD - Combined Type, Attention Deficit Hyperactivity Disorder Combined
- Trial name
- NCT05286762
- Testing
- CTx-1301-Dexmethylphenidate 12.5 mg (titration only), CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose), CTx-1301-Dexmethylphenidate 25mg (randomized fixed dose)
- Where
- 24 sites in United States
- Volunteers
- 103 people
- Sponsor
- Cingulate Therapeutics
Attention Deficit Hyperactivity Disorder
Intervention for Teens With ADHD and Substance Use
Individuals with ADHD are at markedly high risk for increased substance use and Substance Use Disorder (SUD). Given the strong evidence for the negative trajectory of individuals with co-occurring ADHD and substance use…
- Trial name
- NCT02502799
- Testing
- Brief Early Intervention, Parent Training with Adolescent Cognitive Behavioral Therapy, Methylphenidate
- Where
- United States
- Volunteers
- 158 people
- Sponsor
- Florida International University
Attention Deficit Hyperactivity Disorder
CONCERTA Lab School Study
The purpose of this trial is to determine if the study medication, CONCERTA (methylphenidate HCl), is safe and effective in improving academic performance and behavior in children with Attention Deficit Hyperactivity Disorder…
- Trial name
- NCT00799487
- Where
- 3 sites in United States
- Volunteers
- 89 people
- Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
ADHD
Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
To evaluate the efficacy of LDX compared to placebo in adults with ADHD in the adult workplace environment (AWE) setting
- Trial name
- NCT00697515
- Testing
- LDX
- Where
- 5 sites in United States
- Volunteers
- 142 people
- Sponsor
- Shire
Attention-Deficit/Hyperactivity Disorder
Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of TAK-137 in Adults With Attention-Deficit/Hyperactivity Disorder.
The purpose of this study is to characterize the safety and tolerability of TAK-137 when administered as multiple oral doses in adults with attention-deficit/hyperactivity disorder (ADHD).
- Trial name
- NCT02163915
- Testing
- TAK-137
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Takeda
Attention-deficit/Hyperactivity Disorder
Examining Tolerance to CNS Stimulants in ADHD
Although stimulant medication is a well-established treatment for ADHD, it is often necessary for doctors to increase the dose over time to maintain the benefits of the medication.
- Trial name
- NCT02039908
- Testing
- Methylphenidate
- Where
- United States
- Volunteers
- 267 people
- Sponsor
- Florida International University
Attention Deficit Hyperactivity Disorder
Characterization of Dermal Reactions in Pediatric Patients With ADHD Using DAYTRANA
This is a study designed to characterize the dermal response of DAYTRANA. Subjects will visit the study site over a period of approximately 14 weeks.
- Trial name
- NCT00434213
- Testing
- Daytrana
- Where
- 29 sites in United States
- Volunteers
- 309 people
- Sponsor
- Noven Therapeutics
Attention Deficit Hyperactivity Disorder
Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
For children and adolescents, how does SPD503 compare to placebo for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT01244490
- Testing
- Extended-release Guanfacine Hydrochloride, Atomoxetine Hydrochloride
- Where
- 66 sites in United States, Austria and 11 more
- Volunteers
- 338 people
- Sponsor
- Shire
Adult Attention-Deficit Hyperactivity Disorder
Efficacy and Safety Eval of Guanfacine Hydrochloride in Combination With Psychostimulants in Adults (18-65).
This is considered an investigator-initiated clinical research trial, which means that your study doctor is researching a particular medication (in this case a medication that is currently FDA- approved) for the treatment of…
- Trial name
- ADINT2012 (NCT02141113)
- Testing
- Guanfacine Hydrochloride
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Rochester Center for Behavioral Medicine
Attention Deficit Hyperactivity Disorder
Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment
The purpose of this study was to evaluate the effect of SPN-810 for the treatment of impulsive aggression (IA) in adolescents diagnosed with ADHD when taken in conjunction with standard ADHD treatment.
- Trial name
- NCT03597503
- Testing
- SPN-810
- Where
- 38 sites in United States
- Volunteers
- 41 people
- Sponsor
- Supernus Pharmaceuticals, Inc.